About Clonz Biotech Private Limited
Data last updated: 10 January 2026
Clonz Biotech Private Limited is a private limited company based in Hyderabad, Telangana, India. It specialises in biotechnology, a part of the broader life sciences sector. Incorporated on 08 October 2009, the company has been in operation for over 17 years.
Registered with ROC Hyderabad under CIN U24231TG2009PTC065376.
Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.38 Cr. It is led by directors including Venkatakrishna Reddy Vempalli and Venkata Subba Reddy Vempalle.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2024. Office: 542 Synergy Square 2 Mn Park, Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹24.39 Lakh, a decline of 67% compared to the previous year.
The company has a workforce of approximately 46 employees as per the latest available data.
The company is associated with 1 brand - Clonz Biotech. As per MCA filings, the company has open charges of ₹30 Cr and satisfied charges of ₹54.52 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website clonzbio.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressBlock No.9 Building – 9000 Plot No.7 Survey No.542 Synergy Square 2 Mn Park Genome Valley, Kolthur, Hyderabad, Telangana, India – 500078
-
IndustryLife Sciences, Biotechnology
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Clonz Biotech Private Limited
Clonz Biotech Private Limited has one previous CIN (Corporate Identification Number): U24231AP2009PTC065376. The current CIN is U24231TG2009PTC065376, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231TG2009PTC065376 | Current |
| U24231AP2009PTC065376 | Previous |
Associated Brands with Clonz Biotech Private Limited
Clonz Biotech Private Limited operates one associated brand: Clonz Biotech. These brands represent Clonz Biotech Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Comprehensive flight management services are offered for aviation operations. | clonzbio.com |
Business Activity of Clonz Biotech Private Limited
Clonz Biotech Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Clonz Biotech Private Limited
Clonz Biotech Private Limited is audited by Skh & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Skh & Associates | blur-value | blur-value | blur-value |
Board of Directors of Clonz Biotech Private Limited
Clonz Biotech Private Limited is currently managed by 5 directors, with 15 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Venkatakrishna Reddy Vempalli | Director | 09 Sep 2020 | 5 Years 10 Months | Current |
| Venkata Subba Reddy Vempalle | Director | 09 Sep 2020 | 5 Years 10 Months | Current |
| Ditya Vempalli | Additional Director | 04 Feb 2025 | 1 Years 5 Months | Current |
| Srinivas Narshimha Dantu | Whole-Time Director | 31 Oct 2025 | 0 Years 8 Months | Current |
Financials of Clonz Biotech Private Limited FY 2024 filings available
Clonz Biotech Private Limited reported revenue of ₹24.39 Lakh (down 67% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Clonz Biotech Private Limited
As of FY 2023, Clonz Biotech Private Limited's shareholding pattern shows 31.09% by promoters, 68.91% by public shareholders. Public shareholders hold the majority stake, reflecting broad public ownership.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Clonz Biotech Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Mar 2025 | Others | ₹30 Cr | Open |
| 07 Aug 2012 | Department of Biotechnology | ₹54.52 Lakh | Satisfied |
Total charge records: 2 View all charges
Employees and EPFO Compliance at Clonz Biotech Private Limited
Clonz Biotech Private Limited has a workforce of 46 employees as of Apr 05, 2024.
Employee Count & EPFO Data of Clonz Biotech Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Clonz Biotech Private Limited
GSTIN & GST Filing Data of Clonz Biotech Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Clonz Biotech Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Clonz Biotech Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Clonz Biotech Private Limited
MSME Payment Delays by Clonz Biotech Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Clonz Biotech Private Limited
Subsidiaries & Group Companies of Clonz Biotech Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Clonz Biotech Private Limited with ownership details.
MCA Filings & Documents of Clonz Biotech Private Limited
MCA Filings & Documents of Clonz Biotech Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Clonz Biotech Private Limited
Frequently Asked Questions about Clonz Biotech Private Limited
Clonz Biotech Private Limited is an active private limited company in the life sciences sector based in Hyderabad, Telangana, India. It was incorporated on 08 October 2009 (17+ years old) and is registered under CIN U24231TG2009PTC065376. The company has 46 employees.
Clonz Biotech Private Limited reported revenue of ₹24.39 Lakh for FY 2025 (down 67.00% YoY).
The current directors of Clonz Biotech Private Limited are:
- Venkatakrishna Reddy Vempalli
- Venkata Subba Reddy Vempalle
- Ditya Vempalli
- Narayan Das Suryawanshi
- Srinivas Narshimha Dantu
The primary industry of Clonz Biotech Private Limited is life sciences. The company specifically operates in biotechnology. The company is currently active in this sector.
Clonz Biotech Private Limited can be reached at the registered office: Block No.9 Building – 9000 Plot No.7 Survey No.542 Synergy Square 2 Mn Park Genome Valley, Kolthur, Hyderabad, Telangana, India – 500078, or through the website clonzbio.com.
The authorised capital is ₹15 Cr, and the paid-up capital is ₹12.38 Cr.